Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
Learn more about of the top AHA 2021 late-breaking trialswith View from the Thoraxcenter hosts, Professor Nicolas Van Mieghem and DrJoost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL). In this short summary video, they summarise the take-home messages and share their take on how the data will shape patient care and research. Trials covered in detail include: • Aortic Valve Replacement versus… View more
Author(s): Stuart J Head , Ad JJC Bogers , A Pieter Kappetein Added: 3 years ago
Abstract In many patients, comparable results can be achieved either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). The comparison of PCI versus CABG is frequently reported in randomised trials, national registries, multicentre collaborations and single-centre experiences. However, the patients included in these analyses are either highly selected … View more
Author(s): Edward McNulty Added: 3 years ago
The debate over the optimal mode of revascularisation for unprotected left main (ULM) coronary artery disease intensified with the advent of drug-eluting stents (DES). Professional society guidelines addressing ULM disease have been revised at an increasing frequency,1,2 the significance of randomised comparisons has been variously interpreted, and observational comparisons have become a… View more
Research Area(s) / Expertise: Job title: Surgical Director
Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine. Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease. Her… View more
Author(s): William Fearon Added: 2 years ago
In this short interview, Dr William F Fearon (Stanford University School of Medicine, US) discusses the findings from the FAME3 trial. This multicenter, international, randomized, controlled noninferiority trial investigated whether fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar… View more
Author(s): Frederik Zimmermann Added: 2 years ago
In this late-breaking interview from ACC.22, Dr Frederik Zimmermann (Catharina Hospital, NL) outlines the main findings of the FAME 3 Trial. FAME 3 is an international, randomised multicentre trial, that aims to compare the outcomes of fractional flow reserve (FFR)-guided PCI and Coronary Artery Bypass Graft Surgery (CABG) in patients with multivessel coronary artery disease. The results… View more